Alys Pharmaceuticals, Inc., a Boston, MA- and Geneva, Switzerland-based immuno-dermatology focused company, launched with a $100m funding from Medicxi.
Co-founded by Medicxi and several world leading dermatology and scientific experts, including John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Nobel Prize winner Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology), and led by by co-founder and COO Thibaud Portal (formerly Galderma’s Global Head of Prescription Medicines). Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics to develop its pipeline of 14 active programs, targeting multiple dermatological indications, including atopic dermatitis, vitiligo, psoriasis and mastocytosis.
Alys anticipates further organic pipeline growth from its platforms, covering inflammatory diseases, autoimmune diseases, dermatology supportive care for cancer patients and rare dermatoses. Over the next three years, the company aims to deliver between seven to ten clinical Proof-of-Concept (POC) readouts, and potentially at least one program to advance to registrational studies.
To this end, Alys is working with institutions such as Institut Gustave Roussy, UMass Chan Medical School, Icahn School of Medicine at Mount Sinai, Georgia Institute of Technology and Empa, the Swiss Federal Laboratories for Materials Science & Technology.
Medicxi’s Francesco De Rubertis serves as Chairman of the Board.
FinSMEs
12/02/2024